Aileron Therapeutics, a biotech targeting a range of cancers using stapled peptides, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
The Cambridge, MA-based company was founded in 2006 and plans to list on the Nasdaq under the symbol ALRN. BofA Merrill Lynch and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
